Marshall Wace’s Jounce Therapeutics JNCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-39,339
Closed -$119K – 3961
2022
Q2
$119K Buy
+39,339
New +$191K ﹤0.01% 3253
2021
Q4
– Sell
-169,686
Closed -$1.26M – 4445
2021
Q3
$1.26M Sell
169,686
-81,792
-33% -$507K 0.01% 1868
2021
Q2
$1.71M Buy
251,478
+156,739
+165% +$1.3M 0.01% 1510
2021
Q1
$973K Buy
+94,739
New +$1.04M ﹤0.01% 1676
2020
Q3
– Sell
-84,369
Closed -$582K – 2023
2020
Q2
$582K Sell
84,369
-171,770
-67% -$927K ﹤0.01% 1154
2020
Q1
$1.22M Sell
256,139
-217,426
-46% -$1.25M 0.01% 754
2019
Q4
$4.13M Buy
+473,565
New +$2.56M 0.03% 592
2019
Q1
– Sell
-25,999
Closed -$88K – 2139
2018
Q4
$88K Buy
+25,999
New +$121K ﹤0.01% 1388

Other funds holding JNCE

Marshall Wace's JNCE Position: Q3 2022 in Review

Marshall Wace sold out of Jounce Therapeutics (JNCE) in Q3 2022, closing a stake of 39,339 shares — an estimated $119K sold.

Marshall Wace first reported a position in JNCE in Q4 2018 and held it in 8 quarters. The position peaked at $4.13M in Q4 2019. 102 funds tracked by Wall St. Rank hold JNCE as of Q3 2022.

  • Marshall Wace reported no remaining Jounce Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Marshall Wace sold 39,339 Jounce Therapeutics shares in Q3 2022, an estimated $119K.
  • Marshall Wace first reported a position in Jounce Therapeutics in Q4 2018 and held it in 8 quarters.
  • Marshall Wace's Jounce Therapeutics position peaked at $4.13M in Q4 2019.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics as of Q3 2022.

Based on Marshall Wace's 13F filing for Q3 2022, filed 14 Nov 2022.